Clinical Trial

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable). Immunotherapy with atezolizumab, may include changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 1 change
critical Recruitment resumed after suspension 2026-08-06
Trial Details
NCT Number NCT06254911
Lead Sponsor Emory University
Collaborators: National Cancer Institute (NCI), Genentech, Inc.
Conditions Oropharynx Cancer, Stage I
Enrollment 20 participants
Start Date 2023-10-27
Primary Completion 2026-12-16 (estimated)
Study Completion 2026-12-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-05